Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2005 Jul 20;2005(3):CD002857.
doi: 10.1002/14651858.CD002857.pub2.

Uterine muscle relaxant drugs for threatened miscarriage

R Lede  1 , L Duley
Affiliations

Uterine muscle relaxant drugs for threatened miscarriage

R Lede et al. Cochrane Database Syst Rev. .

Abstract

Background: Miscarriage is the spontaneous loss of a pregnancy before the fetus is viable. Uterine muscle relaxant drugs have been used for women at risk of miscarriage in the belief they relax uterine muscle, and hence reduce the risk of miscarriage.

Objectives: To assess the effects for the woman and her baby of uterine muscle relaxant drugs when used for threatened miscarriage.

Search strategy: We searched the Cochrane Pregnancy and Childbirth Group Trials Register (4 May 2004), and the Cochrane Central Register of Controlled Trials (The Cochrane Library, Issue 2, 2004).

Selection criteria: Randomised trials were included, and quasi-randomised trials were excluded. The participants were women with a pregnancy of less than 20 weeks' gestation having a threatened miscarriage. The interventions were any uterine muscle relaxing drugs (including tocolytic and antispasmodic agents) compared with either placebo or no drug. Primary outcomes for the review were miscarriage: defined as spontaneous pregnancy loss before fetal viability, baby death (stillbirth or neonatal death) and maternal death.

Data collection and analysis: Both review authors independently assessed studies for eligibility and trial quality, and extracted data.

Main results: One poor quality trial (170 women) was included. This compared a beta-agonist with placebo. There was a lower risk of intrauterine death associated with the use of a beta-agonist (relative risk (RR) 0.25, 95% confidence interval (CI) 0.12 to 0.51). Preterm birth was the only other outcome reported (RR 1.67, 95% CI 0.63 to 4.38).

Authors' conclusions: There is insufficient evidence to support the use of uterine muscle relaxant drugs for women with threatened miscarriage. Any such use should be restricted to the context of randomised trials.

PubMed Disclaimer

Conflict of interest statement

None known.

Figures

1.1
1.1. Analysis
Comparison 1 Uterine muscle relaxants versus placebo/no relaxants, Outcome 1 Intrauterine death (miscarriage or stillbirth).
1.2
1.2. Analysis
Comparison 1 Uterine muscle relaxants versus placebo/no relaxants, Outcome 2 Preterm birth.
See this image and copyright information in PMC

Update of

  • doi: 10.1002/14651858.CD002857

References

References to studies included in this review

Egypt 1986 {published data only}
    1. Soltan MH. Buphenine and threatened abortion. European Journal of Obstetrics & Gynecology and Reproductive Biology 1986;22:319‐24. - PubMed

References to studies excluded from this review

Bigby 1969 {published data only}
    1. Bigby MAM, Barnard EE, Chatterji S. A clinical trial of isoxsuprine in the treatment of threatened abortion. Journal of Obstetrics and Gynaecology of the British Commonwealth 1969;76:934‐5. - PubMed
Goisis 1975 {published data only}
    1. Goisis M, Candotti G. Treatment of threatened abortion in a serotonin antagonist. Clinico‐statistical data [Sul trattamento delle minacce d'interruzione di gravidanza con un antienteraminico. Rilievi clinico‐statistici]. Minerva Ginecologica 1975;27:773‐8. - PubMed
Hirahara 1998 {published data only}
    1. Hirahara F, Andoh N, Sawai K, Hirabuki T, Uemura T, Minaguchi H. Hyperprolactinemic recurrent miscarriage and results of randomized bromocriptine treatment trials. Fertility and Sterility 1998;70(2):246‐52. - PubMed
Ruppin 1981 {published data only}
    1. Ruppin E, Ruppin J, Chelius HH. A double blind study of the treatment of threatened abortion with fenoterol hydrobromide. Geburtshilfe und Frauenheilkunde 1981;41:218‐21. - PubMed
Souka 1980 {published data only}
    1. Souka AR, Osman M, Sibaie F, Einem MA. Therapeutic value of indomethacin in threatened abortion. Prostaglandins 1980;19:457‐60. - PubMed

Additional references

Alderson 2004
    1. Alderson P, Green S, Higgins JPT, editors. Cochrane Reviewers’ Handbook 4.2.2 [updated December 2003]. In: The Cochrane Library, Issue 1, 2004. Chichester, UK: John Wiley & Sons, Ltd.
Charpentier 1883
    1. Charpentier, editor. Traitè practique des accouchements. París: Bailliers, 1983.
Coggiola 1982
    1. Coggiola F, Scarrone G, Cabiati EG. 3 cases of acute pulmonary edema in pregnant women treated with tocolytics and betamethasone. Minerva Ginecologica 1982;34:191‐4. - PubMed
De Lee 1945
    1. De Lee‐Greenhill, editor. Principios y práctica de la obstetricia. México: Hispano‐Americana, 1945.
Hemminki 1999
    1. Hemminki E, Forssas E. Epidemiology of miscarriage and its relation to other reproductive events in Finland. American Journal of Obsterics and Gynecology 1999;181:396‐401. - PubMed
Lede 2001
    1. Lede R. Personal communication 2001.
León 1967
    1. León J, Corneli O, editors. Manual de obstetricia. Buenos Aires: El Ateneo, 1967.
McBride 1991
    1. McBride WZ. Spontaneous abortion. American Family Physician 1991;43:175‐82. - PubMed
Onoe 1995
    1. Onoe T, Takahashi Y, Noda Y. Ritrodine‐induced neutropenia in two cases of threatened premature delivery. Nippon Sanka Fujinka Gakkei Zasshi 1995;47:283‐6. - PubMed
Schwarcz 1986
    1. Schwarcz R, Duverges C, Diaz A, Fecsina R, editors. Obstetricia. Buenos Aires: El Ateneo, 1986.
Szabo 1996
    1. Szabo I, Szilagyi A. Management of threatened abortion. Early Pregnancy 1996;2:233‐40. - PubMed
USP DI 1999
    1. Drug Information for the Health Care Professional. United State Pharmacopeial Dispensing Information, 19th edition 1999; Vol. 1.
Vermes 1997
    1. Vermes E, Leroy G, Halphen C, Guyon P, Labib M, Stolz JP, et al. Myocardial infarction in a pregnant woman during salbutamol therapy. Archives des Maladies du Coeur et de Vaisseaux 1997;90:1651‐4. - PubMed

References to other published versions of this review

Prendiville 1995
    1. Prendiville WJ. Tocolytics/antispasmodics for threatened miscarriage. [revised 24 March 1993]. In: Enkin MW, Keirse MJNC, Renfrew MJ, Neilson JP, Crowther C (eds.). Pregnancy and Childbirth Module. The Cochrane Pregnancy and Childbirth Database [database on disk and CDROM]. The Cochrane Collaboration; Issue 2, Oxford: Update Software; 1995.

Publication types

LinkOut - more resources